PCRX — Pacira Biosciences Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $24.51
- 30-Day Move
- -8.1%
- Market Cap
- $951M
- Shares Outstanding
- 40,490,000
- P/E Ratio
- 135.22
- P/B Ratio
- 1.61
Pacira Biosciences Inc
A read-only Alphactor snapshot forPacira Biosciences Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$24.51
30-Day Move
-8.1%
Market Cap
$951M
Shares Outstanding
40,490,000
P/E Ratio
135.22
P/B Ratio
1.61
$24.51
-8.1%last 90 delayed daily bars
90D High
$27.16
90D Low
$18.80
Avg Volume
822,176
Gross margin is running at 79.4%, which gives a quick read on operating quality before you open the full model.
Net margin is 97.0%, useful for comparing PCRX against peers in Pharmaceuticals.
PCRX is down 8.1% over the last 30 trading days shown on this page.
Latest operating income is $33M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$44.35
Rule of 40
22.4%
Latest Close
$24.51
30-Day Move
-8.1%
Market Cap
$951M
Shares Outstanding
40,490,000
P/E Ratio
135.22
P/B Ratio
1.61
ROE
1.0%
ROA
56.0%
Gross Margin
79.4%
Operating Margin
99.0%
Net Margin
97.0%
Debt / Equity
0.54
Current Ratio
4.54
Latest Revenue
$726M
Revenue
$726M
Gross Profit
$577M
Operating Income
$33M
Net Income
$7M
Gross Margin
7939.0%
Net Margin
97.0%
Current Ratio
4.54
Debt / Equity
0.54
Fair Value
$44.35
Upside / Downside
+81.0%
Signal
Undervalued
Implied Growth
-3.8%
DCF
$40.65
EPV
$9.12
EV/Rev
$83.29
Growth Assumption
2.9%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
$137M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Altman Z
1.84
Grey
Piotroski
9
Strong (7-9)
Cash Conversion
21.61x
Rule of 40
22.4%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $667M | $71M | $16M | $115M |
| 2023-12-31 | $675M | $87M | $42M | $139M |
| 2024-12-31 | $701M | $98M | $-100M | $179M |
| 2025-12-31 | $726M | $33M | $7M | $137M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Qube Research & Technologies
Filed 2025-05-15
--
--
BlackRock
Filed 2024-05-10
$231M
--
Vanguard Group
Filed 2025-11-07
$134M
-3.9%
Renaissance Technologies
Filed 2025-08-13
$57M
+6.9%
D.E. Shaw
Filed 2026-02-17
$53M
+5.0%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.